{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:11:37Z","timestamp":1784765497525,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Key","award":["2016YFC1200900"],"award-info":[{"award-number":["2016YFC1200900"]}]},{"DOI":"10.13039\/100006190","name":"Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Program of China"},{"name":"National Science and Technology Major Project","award":["2018ZX09301053-004-001"],"award-info":[{"award-number":["2018ZX09301053-004-001"]}]},{"name":"Key Technologies R&D Program of Jilin Province","award":["20160209015YY"],"award-info":[{"award-number":["20160209015YY"]}]},{"name":"Major Technological Program of Changchun City","award":["16ss11"],"award-info":[{"award-number":["16ss11"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.urolonc.2018.12.012","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T20:37:52Z","timestamp":1547843872000},"page":"352.e1-352.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antitumor effect of a dual cancer-specific oncolytic adenovirus on prostate cancer PC-3 cells"],"prefix":"10.1016","volume":"37","author":[{"given":"Chuan-xin","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-quan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-jia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-long","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-bo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-zhen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-yi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2018.12.012_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.steroids.2014.07.004","article-title":"Current state of practice regarding testosterone supplementation therapy in men with prostate cancer","volume":"89","author":"Kovac","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0002","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0959-8049(01)00350-1","article-title":"Estimates of cancer incidence and mortality in Europe in 1995","volume":"38","author":"Bray","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0003","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1568009023333890","article-title":"Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan","volume":"2","author":"Mathijssen","year":"2002","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0005","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0006","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/cncr.30367","article-title":"Informed decision making before prostate-specific antigen screening: initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men","volume":"123","author":"Gokce","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0007","first-page":"1","article-title":"Cancer statistics: updated cancer burden in China","volume":"27","author":"Chen","year":"2015","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2015.07.005","article-title":"Editorial overview: oncolytic viruses\u2013replicating virus therapeutics for the treatment of cancer","volume":"13","author":"Bell","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0009","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tips.2007.05.005","article-title":"Viruses as anticancer drugs","volume":"28","author":"Russell","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0010","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0011","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.molonc.2008.04.001","article-title":"Imaging and cancer: a review","volume":"2","author":"Fass","year":"2008","journal-title":"Mol Oncol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0012","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nrc2289","article-title":"New approaches for imaging tumour responses to treatment","volume":"8","author":"Brindle","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0013","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00259-003-1269-z","article-title":"Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir","volume":"31","author":"Deng","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0014","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.gt.3302278","article-title":"Molecular imaging of gene therapy for cancer","volume":"11","author":"Shah","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fonc.2016.00150","article-title":"The expanding toolbox of in vivo bioluminescent imaging","volume":"6","author":"Xu","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0016","doi-asserted-by":"crossref","first-page":"41210","DOI":"10.1117\/1.2032388","article-title":"Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo","volume":"10","author":"Zhao","year":"2005","journal-title":"J Biomed Opt"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0017","doi-asserted-by":"crossref","first-page":"92935","DOI":"10.1002\/cbic.200500443","article-title":"Firefly luciferase produces hydrogen peroxide as a coproduct in dehydroluciferyl adenylate formation","volume":"7","author":"Fraga","year":"2006","journal-title":"Chembiochem"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0018","doi-asserted-by":"crossref","first-page":"e9364","DOI":"10.1371\/journal.pone.0009364","article-title":"Non-invasive detection of a small number of bioluminescent cancer cells in vivo","volume":"5","author":"Kim","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0019","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1128\/jvi.65.6.3131-3139.1991","article-title":"Characterization of cloned chicken anemia virus DNA that contains all elements for the infectious replication cycle","volume":"65","author":"Noteborn","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/03079459508419046","article-title":"Chicken anaemia virus infection: molecular basis of pathogenicity","volume":"24","author":"Noteborn","year":"1995","journal-title":"Avian Pathol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0021","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1128\/jvi.68.1.346-351.1994","article-title":"A single chicken anemia virus protein induces apoptosis","volume":"68","author":"Noteborn","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0022","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1073\/pnas.94.11.5843","article-title":"Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells","volume":"94","author":"Danen-Van Oorschot","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0023","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.onc.1207224","article-title":"TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells","volume":"23","author":"Guelen","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0024","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/sj.gt.3300876","article-title":"Specific tumor-cell killing with adenovirus vectors containing the apoptin gene","volume":"6","author":"Pietersen","year":"1999","journal-title":"Gene Ther"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2018.12.012_bib0025","first-page":"S118","article-title":"Apoptin, a protein encoded by chicken anemia virus, induces cell death in various human hematologic malignant cells in vitro","volume":"9","author":"Zhuang","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0026","doi-asserted-by":"crossref","first-page":"32494","DOI":"10.1074\/jbc.M112.368282","article-title":"Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt\/beta-catenin pathway in human cancer","volume":"287","author":"Zhang","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0027","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fgene.2016.00083","article-title":"Regulation of the telomerase reverse transcriptase subunit through epigenetic mechanisms","volume":"7","author":"Lewis","year":"2016","journal-title":"Front Genet"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0028","first-page":"7","article-title":"Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) gene","author":"Ramlee","year":"2016","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0029","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/sj.bjc.6605878","article-title":"Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways","volume":"103","author":"Sitaram","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-4598-9-10","article-title":"Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo","volume":"9","author":"Li","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0031","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3892\/ijmm.2012.1077","article-title":"Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma","volume":"30","author":"Liu","year":"2012","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0032","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3892\/ijo.2013.1783","article-title":"Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma","volume":"42","author":"Zhang","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0033","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.taap.2014.08.008","article-title":"Preclinical pharmacology and toxicology study of Ad-hTERT-E1a-Apoptin, a novel dual cancer-specific oncolytic adenovirus","volume":"280","author":"Qi","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0034","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3892\/etm.2014.2086","article-title":"Antitumor effects of a dual cancer-specific oncolytic adenovirus on colorectal cancer in vitro and in vivo","volume":"9","author":"Yang","year":"2015","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0035","first-page":"148","article-title":"[Anti-tumor effects of apoptin gene on human laryngeal carcinoma Hep-2]","volume":"42","author":"Sun","year":"2007","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0036","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc3397","article-title":"Future directions in cancer prevention","volume":"12","author":"Umar","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0037","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.molmed.2012.06.005","article-title":"Hallmarks of cancer: of all cancer cells, all the time?","volume":"18","author":"Floor","year":"2012","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0038","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0039","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0040","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/jcmm.12018","article-title":"Bioluminescence imaging: a shining future for cardiac regeneration","volume":"17","author":"Roura","year":"2013","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0041","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ab.2007.04.018","article-title":"Increase in bioluminescence intensity of firefly luciferase using genetic modification","volume":"366","author":"Fujii","year":"2007","journal-title":"Anal Biochem"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0042","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/iub.134","article-title":"Firefly bioluminescence: a mechanistic approach of luciferase catalyzed reactions","volume":"61","author":"Marques","year":"2009","journal-title":"IUBMB Life"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0043","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cbpa.2014.07.003","article-title":"Beyond D-luciferin: expanding the scope of bioluminescence imaging in vivo","volume":"21","author":"Adams","year":"2014","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0044","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nmeth.2839","article-title":"A synthetic luciferin improves bioluminescence imaging in live mice","volume":"11","author":"Evans","year":"2014","journal-title":"Nat Methods"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0045","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4103\/0971-5916.200887","article-title":"Apoptosis, autophagy & endoplasmic reticulum stress in diabetes mellitus","volume":"144","author":"Demirtas","year":"2016","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0046","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4161\/cbt.5.1.2400","article-title":"Cancer-selective therapy of the future: apoptin and its mechanism of action","volume":"5","author":"Maddika","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0047","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12010-015-1567-5","article-title":"Apoptin as a potential viral gene oncotherapeutic agent","volume":"176","author":"Singh","year":"2015","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0048","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10495-015-1120-6","article-title":"Apoptin interacts with and regulates the activity of protein kinase C beta in cancer cells","volume":"20","author":"Bullenkamp","year":"2015","journal-title":"Apoptosis"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0049","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1002\/ijc.22215","article-title":"Antitumor effects of a recombinant fowlpox virus expressing Apoptin in vivo and in vitro","volume":"119","author":"Li","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0050","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/ijc.24959","article-title":"Antitumor effects of a recombinant pseudotype baculovirus expressing Apoptin in vitro and in vivo","volume":"126","author":"Pan","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0051","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejphar.2010.12.004","article-title":"PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo","volume":"654","author":"Jin","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0052","doi-asserted-by":"crossref","first-page":"27729","DOI":"10.1074\/jbc.M303114200","article-title":"Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis","volume":"278","author":"Danen-Van Oorschot","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0053","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1002\/ijc.23884","article-title":"The C-terminus of apoptin represents a unique tumor cell-enhanced nuclear targeting module","volume":"123","author":"Kuusisto","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0054","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1128\/JVI.78.11.6077-6078.2004","article-title":"Apoptin\/VP3 contains a concentration-dependent nuclear localization signal (NLS), not a tumorigenic selective NLS","volume":"78","author":"Wadia","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.urolonc.2018.12.012_bib0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/18715206113139990309","article-title":"Adenoviral vectors for prodrug activation-based gene therapy for cancer","volume":"14","author":"Doloff","year":"2014","journal-title":"Anticancer Agents Med Chem"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918305064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918305064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:14:33Z","timestamp":1761041673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143918305064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1078143918305064"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.12.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor effect of a dual cancer-specific oncolytic adenovirus on prostate cancer PC-3 cells","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}